Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) FCF Margin (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed FCF Margin for 6 consecutive years, with 1253.33% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 337178.0% to 1253.33% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1353.28% through Dec 2025, up 271799.0% year-over-year, with the annual reading at 1353.28% for FY2025, 271799.0% up from the prior year.
  • FCF Margin for Q4 2025 was 1253.33% at TScan Therapeutics, up from 1349.62% in the prior quarter.
  • The five-year high for FCF Margin was 139.62% in Q3 2023, with the low at 5295.41% in Q1 2024.
  • Average FCF Margin over 5 years is 1414.41%, with a median of 628.77% recorded in 2021.
  • The sharpest move saw FCF Margin crashed -487429bps in 2024, then surged 389168bps in 2025.
  • Over 5 years, FCF Margin stood at 482.87% in 2021, then dropped by -6bps to 513.15% in 2022, then surged by 42bps to 296.63% in 2023, then tumbled by -1459bps to 4625.11% in 2024, then soared by 73bps to 1253.33% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 1253.33%, 1349.62%, and 1161.87% for Q4 2025, Q3 2025, and Q2 2025 respectively.